Literature DB >> 9599023

Genomic organization and promoter characterization of human CXCR4 gene.

A Caruz1, M Samsom, J M Alonso, J Alcami, F Baleux, J L Virelizier, M Parmentier, F Arenzana-Seisdedos.   

Abstract

CXCR4 is the receptor for the CXC chemokine SDF1 that has essential functions on embryo organogenesis, immunological functions and T lymphocyte trafficking. Recently, CXCR4 has drawn unexpected attention as it was recently identified as a co-factor required for entry of lymphotropic HIV isolates in CD4+ T lymphocytes. CXCR4 is the only SDF1 receptor identified so far. This suggests that CXCR4 expression is critical for the biological effects of SDF1. To investigate the mechanisms controlling both the constitutive and induced expression of CXCR4 receptors we have isolated and characterized the promoter region and determined the genomic structure of the human gene. The CXCR4 gene contains two exons separated by an intronic sequence. A 2.6 kb 5'-flanking region located upstream the CXCR4 open reading frame contains a TATA box and the transcription start site characteristic of a functional promoter. This region also contains putative consensus binding sequences for different transcription factors, some of them associated with the hemopoiesis and lymphocyte development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9599023     DOI: 10.1016/s0014-5793(98)00359-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  44 in total

Review 1.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

2.  CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer.

Authors:  Ying Gao; Chunyu Li; Min Nie; Yao Lu; Shunsen Lin; Peng Yuan; Xun Sun
Journal:  Tumour Biol       Date:  2014-01-07

3.  Enhanced migration and CXCR4 over-expression in fibroblasts with telomerase reconstitution.

Authors:  Yi Qu; Meng Mao; Xihong Li; Lin Zhang; Xiang Huang; Chunlei Yang; Fengyang Zhao; Ying Xiong; Dezhi Mu
Journal:  Mol Cell Biochem       Date:  2008-03-25       Impact factor: 3.396

4.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

5.  Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer.

Authors:  Xiuyun Jiang; Kevin M Sullivan; Yongwoo David Seo; Florencia G Jalikis; Kimberly S Smythe; Arezou Abbasi; Marissa Vignali; James O Park; Sara K Daniel; Seth M Pollack; Teresa S Kim; Raymond Yeung; Ian Nicholas Crispe; Robert H Pierce; Harlan Robins; Venu G Pillarisetty
Journal:  Clin Cancer Res       Date:  2019-04-02       Impact factor: 12.531

Review 6.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

7.  NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation.

Authors:  Louic S Vermeer; Gilbert O Fruhwirth; Pahini Pandya; Tony Ng; A James Mason
Journal:  J Proteome Res       Date:  2012-04-02       Impact factor: 4.466

8.  Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Takuo Hasegawa; Kohei Ichihara; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  Mol Clin Oncol       Date:  2017-04-04

9.  Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus.

Authors:  Li-Dan Zhao; Di Liang; Xiang-Ni Wu; Yang Li; Jing-Wen Niu; Chen Zhou; Li Wang; Hua Chen; Wen-Jie Zheng; Yun-Yun Fei; Fu-Lin Tang; Yong-Zhe Li; Feng-Chun Zhang; Wei He; Xue-Tao Cao; Xuan Zhang
Journal:  Cell Mol Immunol       Date:  2016-09-26       Impact factor: 11.530

10.  Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.

Authors:  Lauren K Dunn; Khalid S Mohammad; Pierrick G J Fournier; C Ryan McKenna; Holly W Davis; Maria Niewolna; Xiang Hong Peng; John M Chirgwin; Theresa A Guise
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.